The virosomal influenza vaccine Invivac ®: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad ®) in elderly subjects

Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad ® (Chiron) and Invivac...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-11, Vol.24 (44), p.6629-6631
Main Authors: de Bruijn, I.A., Nauta, J., Gerez, L., Palache, A.M.
Format: Article
Language:English
Subjects:
Adjuvant
Applied microbiology
Biological and medical sciences
Confidence intervals
Elderly
Fundamental and applied biological sciences. Psychology
Immunogenicity
Improved immunogenicity
Influenza
Influenza vaccine
Microbiology
Objectives
Statistical methods
Tolerability
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virosomal
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad ® (Chiron) and Invivac ® (Solvay Pharmaceuticals). The present clinical study was a randomized, endpoint-blind, parallel group study in elderly subjects aged 61 years and older to investigate the safety and immunogenicity of these vaccines as compared to a standard influenza vaccine Invivac ® (Solvay Pharmaceuticals). The three vaccines had similar immunogenicity results, whereas the tolerability profile of Invivac was better as compared to Fluad.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2006.05.035